J B. Milstien - JoVE Visualize

Showing results (21-30 of 29) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 29 results.

Journal of Virology|October 1, 1973

Reassortment of simian virus 40 DNA during serial undiluted passageM A Martin, L D Gelb, G C Fareed, et al.

Vaccine|March 1, 1996

Global DTP manufacturing capacity and capability. Status report: January 1995J B Milstien, B G Gellin, M Kane, et al.

Vaccine|February 13, 2001

Ensuring vaccine safety in immunization programmes--a WHO perspectiveL Jodar, P Duclos, J B Milstien, et al.

Lancet (London, England)|May 28, 1994

Paralytic poliomyelitis: seasoned strategies, disappearing diseaseH F Hull, N A Ward, B P Hull, et al.

Biologicals : Journal of the International Association of Biological Standardization|December 1, 1993

The WHO-EPI initiative for the global eradication of poliomyelitisN A Ward, J B Milstien, H F Hull, et al.

Obstetrics and Gynecology|September 1, 1989

Neonatal anuria with maternal angiotensin-converting enzyme inhibitionF W Rosa, L A Bosco, C F Graham, et al.

Vaccine|October 28, 2008

Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?P Lydon, R Levine, M Makinen, et al.

Journal of the National Cancer Institute|October 1, 1976

Safety of viral vaccine cell substrates: a reevaluationJ C Petricciani, J B Milstien, A S Seifried, et al.

American Journal of Epidemiology|February 1, 1988

Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three yearsF E Shaw, D J Graham, H A Guess, et al.

Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 29 results.

Journal of Virology|October 1, 1973

Reassortment of simian virus 40 DNA during serial undiluted passageM A Martin, L D Gelb, G C Fareed, et al.

Vaccine|March 1, 1996

Global DTP manufacturing capacity and capability. Status report: January 1995J B Milstien, B G Gellin, M Kane, et al.

Vaccine|February 13, 2001

Ensuring vaccine safety in immunization programmes--a WHO perspectiveL Jodar, P Duclos, J B Milstien, et al.

Lancet (London, England)|May 28, 1994

Paralytic poliomyelitis: seasoned strategies, disappearing diseaseH F Hull, N A Ward, B P Hull, et al.

Biologicals : Journal of the International Association of Biological Standardization|December 1, 1993

The WHO-EPI initiative for the global eradication of poliomyelitisN A Ward, J B Milstien, H F Hull, et al.

Obstetrics and Gynecology|September 1, 1989

Neonatal anuria with maternal angiotensin-converting enzyme inhibitionF W Rosa, L A Bosco, C F Graham, et al.

Vaccine|October 28, 2008

Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?P Lydon, R Levine, M Makinen, et al.

Journal of the National Cancer Institute|October 1, 1976

Safety of viral vaccine cell substrates: a reevaluationJ C Petricciani, J B Milstien, A S Seifried, et al.

American Journal of Epidemiology|February 1, 1988

Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three yearsF E Shaw, D J Graham, H A Guess, et al.

Pageof 3